The aim of this research is to discover new chemical entities that are efficacious as anti-addictive agents. We will synthesize target compounds that are structurally related to known Iboga alkaloids. This will involve chemical synthesis of novel compounds and general functional group manipulation. In Phase 1 of this proposal 5-8 analogs of the synthetic Iboga alkaloid 18-MC will be synthesized in parallel for subsequent testing in both in vitro and in vivo models of drug seeking behavior. Success in Phase 1 will set the stage for a more intensive chemistry and biology discovery program in Phase 2.

Proposed Commercial Applications

The ultimate goal of this research is to commercialize a new chemical entity which treats the addictive effects of one or more drugs of abuse, such as cocaine, amphetamine, alcohol or nicotine.

Agency
National Institute of Health (NIH)
Institute
National Institute on Drug Abuse (NIDA)
Type
Small Business Innovation Research Grants (SBIR) - Phase I (R43)
Project #
1R43DA012078-01
Application #
2716718
Study Section
Special Emphasis Panel (ZRG3-SSS-Z (01))
Project Start
1998-09-01
Project End
1999-06-30
Budget Start
1998-09-01
Budget End
1999-06-30
Support Year
1
Fiscal Year
1998
Total Cost
Indirect Cost
Name
Albany Molecular Research, Inc.
Department
Type
DUNS #
City
Albany
State
NY
Country
United States
Zip Code
12212